Imiquimod Availability: What Providers and Prescribers Need to Know in 2026

Imiquimod remains an essential tool in dermatology and primary care for managing external genital and perianal warts, actinic keratosis, and superficial basal cell carcinoma. While no national FDA shortage is active as of 2026, prescribers are reporting patient complaints about difficulty filling imiquimod prescriptions. This briefing provides a practical, clinically grounded overview of the current supply situation, prescribing implications, and patient support strategies.

Current Supply Status (2026)

As of 2026, imiquimod is not on the FDA Drug Shortage Database. Generic imiquimod 5% cream has robust multi-manufacturer supply (Viatris/Mylan, Taro, Apotex, Glenmark, Cosette, Padagis, Encube, Strides Pharma). Zyclara (imiquimod 3.75%) remains a branded product from Bausch Health with more limited distribution.

The primary access barrier is not a manufacturing shortage but rather a stocking/distribution gap: many community pharmacies do not keep imiquimod in regular inventory due to relatively low and intermittent demand. This is particularly true for smaller, independent pharmacies. Patients with new or refill prescriptions may encounter delayed access as pharmacies order to fill.

Aldara Discontinuation: Clinical Implications

The brand-name Aldara (imiquimod 5% cream) has been discontinued in the United States. Clinicians still prescribing "Aldara" by brand may create confusion at the pharmacy counter. Recommend prescribing "imiquimod 5% cream" generically to avoid delays caused by brand-name lookup errors. FDA-approved generic imiquimod 5% cream is therapeutically equivalent in all approved indications.

Strength-to-Indication Mapping: Critical for Access

Imiquimod has three approved concentrations, each with distinct indications and dosing. Prescribing the correct strength not only ensures clinical appropriateness but affects which pharmacy carries the product:

Imiquimod 5% cream (generic, formerly Aldara): AK (face/scalp, 2x weekly for 16 weeks), sBCC (5x weekly for 6 weeks), EGW (3x weekly up to 16 weeks). Most widely stocked by pharmacy chains.

Imiquimod 3.75% cream (Zyclara): AK (daily for two 2-week cycles with a 2-week rest), EGW (daily for up to 8 weeks). More limited stocking; may require prior auth on some plans.

Imiquimod 2.5% cream (Zyclara): Indicated for AK only. Least commonly stocked.

For most clinical scenarios, generic imiquimod 5% cream is the most accessible and cost-effective option. If you have a clinical reason for Zyclara (e.g., patient preference for a shorter AK cycle or documented intolerance to the 5% formulation), document the rationale in case prior auth is required.

Insurance and Prior Authorization Considerations

Generic imiquimod 5% is typically covered as a Tier 1 or Tier 2 formulary item on commercial insurance plans, with low or no copay. Zyclara (3.75%), as a branded product, may be subject to Tier 3 placement, step therapy (requiring a trial of 5% generic first), or prior authorization.

Medicare Part D coverage varies by plan; check the patient's formulary. No manufacturer Patient Assistance Programs (PAPs) are currently available for generic imiquimod. GoodRx coupons can reduce cash pay cost to $28–$30 for a 12-packet box of the 5% cream.

When to Switch: Evidence-Based Alternatives by Indication

When imiquimod is unavailable or not tolerated, consider these alternatives:

External genital/perianal warts: Podofilox 0.5% solution/gel (self-applied, BID x 3 days on/4 days off, up to 4 cycles); sinecatechins 15% ointment (TID up to 16 weeks); in-office cryotherapy or TCA.

Actinic keratosis: Topical fluorouracil 5% (Efudex) BID x 2–4 weeks; diclofenac 3% gel (Solaraze) BID x 60–90 days; photodynamic therapy (PDT) for large-field AK; cryotherapy for isolated lesions.

Superficial BCC: Topical fluorouracil 5% BID x 3–6 weeks; PDT for thin, superficial lesions; surgical excision or curettage/electrodesiccation for lesions where topical therapy isn't appropriate.

Tools to Help Your Patients Fill Imiquimod Prescriptions

Directing patients to call pharmacies themselves is time-consuming and often ineffective. medfinder for providers offers a solution: patients provide their medication, dosage, and ZIP code, and medfinder calls pharmacies on their behalf to find which ones have imiquimod in stock. Results are texted directly to the patient, reducing calls to your office and minimizing treatment delays.

For a comprehensive guide to pharmacy access strategies for patients, see our provider's guide to helping patients find imiquimod in stock.